14 July, 2017
(NASDAQ:CARA) in a report released on Friday, June 30th, MarketBeat.com reports. The share price has moved backward from its 20 days moving average, trading at a distance of -27.58% and stays -22.5% away from its 50 days moving average.
A number of other research analysts have also commented on the stock. Cara Therapeutics now has an average rating of Buy and an average target price of $25.68. Laidlaw lifted their price target on shares of Cara Therapeutics from $17.00 to $20.00 and gave the company a buy rating in a report on Friday, March 10th. Needham & Company LLC restated a buy rating and issued a $23.00 price target on shares of Cara Therapeutics in a research note on Wednesday, June 21st. Cantor Fitzgerald set a $24.00 price target on shares of Cara Therapeutics and gave the company a buy rating in a report on Friday, March 10th. Wall Street is only getting more bullish on the stock, with 5 of analysts who cover CARA having a buy-equivalent rating. Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. 8797835 shares were traded on Cara Therapeutics Inc's last session. The stock had a trading volume of 3,690,186 shares. Keeping an eye on the volatile stocks may help spot market abnormalities. While the company's share hit the 52 week high on 06/27/17 stationing the value of $28.50. The company has a 50-day moving average price of $18.44 and a 200-day moving average price of $15.55.
Over the past 2 quarters, Cara Therapeutics, Inc. The company is expected to report EPS as high as $-0.33 and as low as $-0.79 per share. During the same period in the previous year, the business earned ($0.39) EPS. Equities analysts predict that Cara Therapeutics will post ($2.44) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of USA and global trademark and copyright law.
06/30/2017 - Cara Therapeutics Inc had its " rating reiterated by analysts at Stifel Nicolaus.
In other Cara Therapeutics news, Director Dean Slagel sold 250,000 shares of the stock in a transaction that occurred on Thursday, June 29th. A total volume of 8.79 million shares were traded versus to average volume of 2.51 million shares. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. However the six-month change in the insider ownership was recorded 2.64%, as well as three-month change in the institutional ownership was recorded 0.03%.
Several large investors have recently modified their holdings of CARA. FMR LLC bought a new position in Cara Therapeutics during the fourth quarter valued at approximately $845,000.
As the next earnings season comes into focus, investors will be keeping watch on the performance of companies that they own. Wells Fargo & Company MN now owns 30,664 shares of the biopharmaceutical company's stock worth $563,000 after buying an additional 6,713 shares during the last quarter. Tiedemann Wealth Management LLC raised its position in Cara Therapeutics by 7.5% in the first quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Cara Therapeutics by 37.4% in the fourth quarter.
FrédériqueMenzaghi, Ph.D., vice president of research and development at Cara, said the data will inform the design of a planned Oral CR845 pruritus clinical program in the non-dialysis CKD-aP population, which the company is planning to start later this year. CR845 is a peripherally acting kappa opioid receptor agonist now in development for the treatment of acute and chronic pain and pruritus, said Cara.
